Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Announces Target Price $30
ClearPoint Neuro, Together With Its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI
The Five-year Returns Have Been Fantastic for ClearPoint Neuro (NASDAQ:CLPT) Shareholders Despite Underlying Losses Increasing
B. Riley Adjusts Price Target on ClearPoint Neuro to $28 From $20, Maintains Buy Rating
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025
ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating
UniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Stifel Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Raises Target Price to $25
ClearPoint Neuro Analyst Ratings
We Think ClearPoint Neuro (NASDAQ:CLPT) Can Afford To Drive Business Growth
Here's Why We're Not Too Worried About ClearPoint Neuro's (NASDAQ:CLPT) Cash Burn Situation
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
Trending Industry Today: Tesla Leads Losses In Brain-Computer Interface Stocks
Stifel Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Raises Target Price to $19
ClearPoint Neuro's Earnings Call Highlights Robust Growth
Earnings Call Summary | ClearPoint Neuro(CLPT.US) Q4 2024 Earnings Conference
ClearPoint Neuro | 10-K: FY2024 Annual Report
ClearPoint Neuro Q4 EPS $(0.20) Misses $(0.16) Estimate, Sales $7.77M Miss $8.23M Estimate
ClearPoint Neuro | 8-K: ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35%